P/E ratio for ADMA Biologics (ADMA)
P/E ratio as of May 2024 (TTM): -33.7
According to ADMA Biologics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -33.7. At the end of 2022 the company had a P/E ratio of -11.4.
P/E ratio history for ADMA Biologics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -11.4 | 328.95% |
| 2021 | -2.66 | 20.06% |
| 2020 | -2.22 | -50.14% |
| 2019 | -4.44 | 171.5% |
| 2018 | -1.64 | -1.25% |
| 2017 | -1.66 | -47.55% |
| 2016 | -3.16 | -31.86% |
| 2015 | -4.64 | -24.85% |
| 2014 | -6.17 | 88.3% |
| 2013 | -3.28 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | 79.6 | -336.13% | 🇺🇸 USA |
 Novavax NVAX | -0.6551 | -98.06% | 🇺🇸 USA |
 Cel-Sci
CVM | -1.92 | -94.30% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.